Effect of rivaroxaban versus apixaban on treatment of cerebral venous thrombosis

Effect of rivaroxaban versus apixaban on treatment of cerebral venous thrombosis: a randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N451

Enrollment

Registered

2022-12-24

Start date

2022-12-22

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral venous thrombosis. Cerebral infarction due to thrombosis of unspecified precerebral artery

Interventions

Intervention 1: Intervention group: Rivaroxaban tablets 15 mg twice a day for 3 weeks and then 20 mg daily for 6 months. Intervention 2: Control group: Apixaban tablets 10 mg twice a day for 3 weeks a

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age 18 to 80 years Cerebral venous thrombosis

Exclusion criteria

Exclusion criteria: Contraindication o anticoagulant therapy Brain tumor

Design outcomes

Primary

Measure	Time frame
Functional impairment. Timepoint: 90 days after intervention. Method of measurement: Using modified Rankin Scale (mRS).	—

Secondary

Measure	Time frame
Complication of cerebral hemorrhage. Timepoint: During the 6-month follow-up period. Method of measurement: Using brain CT scan.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Maryam Ghasemi

Hamedan University of Medical Sciences

maryam.gh1989@yahoo.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026